What is Zacks Small Cap’s Estimate for ADAP Q1 Earnings?

Adaptimmune Therapeutics plc (NASDAQ:ADAP) – Analysts at Zacks Small Cap issued their Q1 2025 EPS estimates for Adaptimmune Therapeutics in a report released on Tuesday, March 25th. Zacks Small Cap analyst M. Kim forecasts that the biotechnology company will post earnings of ($0.23) per share for the quarter. The consensus estimate for Adaptimmune Therapeutics’ current full-year earnings is ($0.14) per share. Zacks Small Cap also issued estimates for Adaptimmune Therapeutics’ Q2 2025 earnings at ($0.18) EPS, Q3 2025 earnings at ($0.10) EPS, Q4 2025 earnings at ($0.06) EPS, FY2025 earnings at ($0.57) EPS and FY2026 earnings at ($0.11) EPS.

Adaptimmune Therapeutics (NASDAQ:ADAP) last announced its earnings results on Monday, March 24th. The biotechnology company reported ($0.26) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.09). The business had revenue of $3.22 million during the quarter, compared to analysts’ expectations of $16.56 million. Adaptimmune Therapeutics had a negative return on equity of 74.15% and a negative net margin of 25.43%.

ADAP has been the topic of a number of other reports. StockNews.com began coverage on shares of Adaptimmune Therapeutics in a report on Friday, March 21st. They issued a “buy” rating on the stock. Scotiabank dropped their target price on shares of Adaptimmune Therapeutics from $3.15 to $1.40 and set a “sector outperform” rating on the stock in a research note on Friday, March 21st. Wells Fargo & Company reduced their target price on shares of Adaptimmune Therapeutics from $2.00 to $1.50 and set an “equal weight” rating for the company in a research report on Friday, March 21st. Finally, Guggenheim lowered their price target on shares of Adaptimmune Therapeutics from $3.00 to $1.75 and set a “buy” rating on the stock in a report on Wednesday. One analyst has rated the stock with a hold rating and five have given a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $1.93.

Adaptimmune Therapeutics Stock Down 6.4 %

ADAP stock opened at $0.21 on Thursday. The stock has a market cap of $52.71 million, a P/E ratio of -0.94 and a beta of 2.52. The company has a current ratio of 3.85, a quick ratio of 3.82 and a debt-to-equity ratio of 0.62. The stock’s fifty day simple moving average is $0.51 and its two-hundred day simple moving average is $0.67. Adaptimmune Therapeutics has a 1-year low of $0.20 and a 1-year high of $1.55.

Hedge Funds Weigh In On Adaptimmune Therapeutics

Several large investors have recently modified their holdings of the business. Jane Street Group LLC boosted its holdings in Adaptimmune Therapeutics by 130.4% in the 3rd quarter. Jane Street Group LLC now owns 174,157 shares of the biotechnology company’s stock worth $166,000 after buying an additional 98,581 shares during the period. Virtu Financial LLC lifted its position in shares of Adaptimmune Therapeutics by 27.5% during the third quarter. Virtu Financial LLC now owns 101,008 shares of the biotechnology company’s stock worth $96,000 after acquiring an additional 21,769 shares in the last quarter. FMR LLC lifted its position in shares of Adaptimmune Therapeutics by 3.0% during the third quarter. FMR LLC now owns 1,740,900 shares of the biotechnology company’s stock worth $1,655,000 after acquiring an additional 50,419 shares in the last quarter. Two Sigma Advisers LP boosted its holdings in shares of Adaptimmune Therapeutics by 492.0% in the fourth quarter. Two Sigma Advisers LP now owns 70,735 shares of the biotechnology company’s stock worth $38,000 after acquiring an additional 58,787 shares during the period. Finally, Two Seas Capital LP purchased a new position in shares of Adaptimmune Therapeutics in the fourth quarter valued at $7,992,000. Hedge funds and other institutional investors own 31.37% of the company’s stock.

Adaptimmune Therapeutics Company Profile

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.